Letter

Drug prices

The ranibizumab saga of drug profiteering

BMJ 2008; 337 doi: 10.1136/bmj.a1532 (Published 3 September 2008)
Cite this as: BMJ 2008;337:a1532

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Andrew C K Lee, clinical lecturer in public health1,
  2. John Radford, director of public health2
  1. 1School of Health and Related Research, University of Sheffield, Sheffield S1 4DA
  2. 2Rotherham Primary Care Trust, Rotherham S66 1YY
  1. andrew.lee{at}sheffield.ac.uk

    The National Institute for Health and Clinical Excellence (NICE) recently sanctioned the use of ranibizumab for age related macular degeneration, having originally concluded it would be cost effective only if limited to treating one eye, which could jeopardise functional vision.1 2 The exorbitant price …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular